Gilead Sciences, Inc.
GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment ofā¦ read more
Healthcare
Drug ManufacturersāGeneral
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$144.81
Price-0.58%
-$0.84
1Y
Price
Market Cap
$179.792b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-128.2%
EBITDA Margin-134.5%
Net Profit Margin+47.3%
Free Cash Flow Margin-128.2%
EBITDA Margin-134.5%
Net Profit Margin+47.3%
Free Cash Flow MarginRevenue
$30.456b
+3.4%
1y CAGR+4.0%
3y CAGR+2.8%
5y CAGREarnings
-$3.240b
-138.1%
1y CAGR+481.1%
3y CAGR+366.7%
5y CAGREPS
-$2.67
-139.4%
1y CAGR+484.4%
3y CAGR+369.2%
5y CAGRBook Value
$11.744b
$49.362b
Assets$37.618b
Liabilities$26.246b
DebtDebt to Assets
53.2%
41.3x
Debt to EBITDAFree Cash Flow
$13.199b
+39.6%
1y CAGR+23.4%
3y CAGR+14.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company